- Home
- SENEB vs ICUCW Comparison
SENEB vs ICUCW Comparison
Compare SENEB & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- ICUCW
- Stock Information
- Founded
- SENEB 1949
- ICUCW N/A
- Country
- SENEB United States
- ICUCW United States
- Employees
- SENEB N/A
- ICUCW 12
- Industry
- SENEB Packaged Foods
- ICUCW Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- ICUCW Health Care
- Exchange
- SENEB Nasdaq
- ICUCW Nasdaq
- Market Cap
- SENEB N/A
- ICUCW N/A
- IPO Year
- SENEB N/A
- ICUCW 2021
- Fundamental
- Price
- SENEB $73.70
- ICUCW $0.03
- Analyst Decision
- SENEB
- ICUCW
- Analyst Count
- SENEB 0
- ICUCW 0
- Target Price
- SENEB N/A
- ICUCW N/A
- AVG Volume (30 Days)
- SENEB 186.0
- ICUCW N/A
- Earning Date
- SENEB 02-06-2025
- ICUCW N/A
- Dividend Yield
- SENEB N/A
- ICUCW N/A
- EPS Growth
- SENEB 23.82
- ICUCW N/A
- EPS
- SENEB 5.83
- ICUCW N/A
- Revenue
- SENEB $1,482,656,000.00
- ICUCW N/A
- Revenue This Year
- SENEB N/A
- ICUCW N/A
- Revenue Next Year
- SENEB N/A
- ICUCW N/A
- P/E Ratio
- SENEB $12.85
- ICUCW N/A
- Revenue Growth
- SENEB N/A
- ICUCW N/A
- 52 Week Low
- SENEB $45.00
- ICUCW N/A
- 52 Week High
- SENEB $73.70
- ICUCW N/A
- Technical
- Relative Strength Index (RSI)
- SENEB 90.77
- ICUCW N/A
- Support Level
- SENEB $62.16
- ICUCW N/A
- Resistance Level
- SENEB $64.36
- ICUCW N/A
- Average True Range (ATR)
- SENEB 0.00
- ICUCW 0.00
- MACD
- SENEB -0.33
- ICUCW 0.00
- Stochastic Oscillator
- SENEB 0.00
- ICUCW 0.00
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.